Bora Pharmaceuticals Completes Acquisition of GSK’s Canadian Facility
Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters.
Bora Pharmaceuticals announced on Dec. 1, 2020 that it has completed its acquisition of GlaxoSmithKline (GSK)’s Mississauga, Ontario, Canada facility.
Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters, a company press release said. The new facility will allow Bora to expand its range of dosage forms while it works to supply formulation development and manufacturing services globally.
“Completing the acquisition marks a major step in our expansion into North America, bringing us closer to many of our current and future customers,” said Bobby Sheng, CEO of Bora Pharmaceuticals, in the press release. “The Mississauga site strengthens our existing state-of-the-art manufacturing network, broadening our capabilities and almost doubling our number of talented colleagues, so that we can continue to support the current and future needs of our customers.”
Source: Bora
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
